Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by Geri Gentry on Nov 8th, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.57.

NMRA has been the topic of several recent analyst reports. Weiss Ratings raised Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Royal Bank Of Canada dropped their price objective on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th.

View Our Latest Analysis on NMRA

Insider Activity

In related news, insider Daljit Singh Aurora sold 91,690 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1.50, for a total transaction of $137,535.00. Following the completion of the transaction, the insider owned 48,750 shares in the company, valued at $73,125. This represents a 65.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 453,833 shares of company stock worth $701,219 over the last 90 days. 26.94% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Siren L.L.C. raised its holdings in Neumora Therapeutics by 35.1% in the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock worth $16,571,000 after purchasing an additional 2,209,039 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Neumora Therapeutics in the 2nd quarter worth about $13,246,000. Perceptive Advisors LLC purchased a new stake in shares of Neumora Therapeutics in the 1st quarter worth about $9,953,000. ICONIQ Capital LLC bought a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at about $4,350,000. Finally, Johnson & Johnson bought a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at about $3,144,057. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Trading Up 3.3%

Shares of NMRA opened at $0.50 on Friday. The stock has a market capitalization of $94.57 million, a P/E ratio of -0.41 and a beta of 3.12. Neumora Therapeutics has a twelve month low of $0.32 and a twelve month high of $3.65. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. The firm has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $1.74.

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. On average, research analysts anticipate that Neumora Therapeutics will post -0.84 EPS for the current year.

About Neumora Therapeutics

(Get Free Report)

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.